Table 1.
ECT and MST dataset details for patients included in analysis.
| ECT | MST | |
|---|---|---|
| N | 22 | 22 |
| Age (median (IQR)) | 46.5 (32, 61) | 47.5 (40.75, 52) |
| Gender (Male/Female) | 8/12 (2 unknown) | 11/11 |
| HAM-D pre (median (IQR)) | 23 (22, 24) (HAMD-17) | 26.5 (24, 29) (HAMD-24) |
| HAM-D post (median (IQR)) | 10 (8.5, 19) (HAMD-17) | 20 (19, 26) (HAMD-24) |
| Number of treatments received (median (IQR)) | 14 (10, 17.5) | 24 (18, 24) |
| Remission rate | 63% | 21% |
| Medications | ||
| Antidepressant | 89% | 65% |
| Antipsychotic | 42% | 25% |
| Anxiolytics | 32% | 15% |
| Stimulants | 11% | 15% |
| Sedative | 68% | 35% |
ECT dataset details were from Voineskos et al., 2016 [35] and further correspondence. MST dataset details were from Daskalakis et al., 2020 [36] and further correspondence. Remission rate was calculated as a percentage of the included patients in our analysis from the cohort that showed equal or larger than 50% decrease in symptom severity.